DDInter875 DDInter492
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
Deflazacort {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esterified estrogens
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Cinoxacin
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Deflazacort may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Deflazacort may lead to a major life threatening interaction when taken with Cinoxacin
Deflazacort may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live